Genmab A/S Q3 2026 Earnings Recap

Genmab’s shares fell 1.4% after earnings, a roughly flat reaction. Revenue and adjusted operating profit grew, while the call highlighted positive late-stage trial results and continued commercial growth; the transcript does not identify a specific source of investor disappointment.

Key Takeaways

• Total revenue increased 22% and adjusted operating profit rose 9%, according to management.
• EPKINLY sales were $491 million for the first nine months, up 47% year over year; management cited growing adoption in the U.S. and an encouraging launch of the second-line FL combination in Japan.
• TIVDAK sales totaled $131 million for the first nine months, up 9% year over year, with growth in Japan and Europe.
• Management reported three positive phase III readouts in October: EPKINLY in frontline DLBCL, Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line head and neck cancer.
• Genmab expects the next petosemtamab milestone, the LiGeR-HN2 trial in second- and third-line head and neck cancer, in the first quarter of 2027.